Ventricular Structure, Function, and Focal Fibrosis in Anabolic Steroid Users: a CMR Study

Overview

Journal Eur J Appl Physiol

Specialty Physiology

Date 2014 Jan 28

PMID 24463601

Citations 8

Authors

Peter J Angell

Tevfik F Ismail

Andrew Jabbour

Gillian Smith

Annette Dahl

Ricardo Wage

Greg Whyte

Daniel J Green

Sanjay Prasad

Keith George

Affiliations

Soon will be listed here.

Abstract

Purpose: Anabolic steroid (AS) misuse is widespread amongst recreational bodybuilders; however, their effects on the cardiovascular system are uncertain. Our aim was to document the impact of AS use on cardiac structure, function and the presence of focal fibrosis using the gold standard cardiovascular magnetic resonance imaging (CMR).

Methods: A cross-sectional cohort design was utilised with 21 strength-trained participants who underwent CMR imaging of the heart and speckle-tracking echocardiography. Thirteen participants (30 ± 5 years) taking AS for at least 2 years and currently on a "using"-cycle were compared with age and training-matched controls (n = 8; 29 ± 6 years) who self-reported never having taken AS (NAS).

Results: AS users had higher absolute left ventricular (LV) mass (220 ± 45 g) compared to NAS (163 ± 27 g; p < 0.05) but this difference was removed when indexed to fat-free mass. AS had a reduced right ventricular (RV) ejection fraction (AS 51 ± 4 % vs. NAS 59 ± 5 %; p < 0.05) and a significantly lower left ventricular E':A' myocardial tissue velocity ratio [AS 0.99(0.54) vs. NAS 1.78(0.46) p < 0.05] predominantly due to greater tissue velocities with atrial contraction. Peak LV longitudinal strain was lower in AS users (AS -14.2 ± 2.7 % vs. NAS -16.6 ± 1.9 %; p < 0.05). There was no evidence of focal fibrosis in any participant.

Conclusions: AS use was associated with significant LV hypertrophy, albeit in-line with greater fat-free mass, reduced LV strain, diastolic function, and reduced RV ejection fraction in male bodybuilders. There was, however, no evidence of focal fibrosis in any AS user.

Citing Articles

Echocardiography in the cardiac assessment of young athletes: a 2025 guideline from the British Society of Echocardiography (endorsed by Cardiac Risk in the Young).

Oxborough D, George K, Cooper R, Bhatia R, Ramcharan T, Zaidi A Echo Res Pract. 2025; 12(1):7.

PMID: 40083035 PMC: 11907977. DOI: 10.1186/s44156-025-00069-0.

The athletes heart-from acute stimulus to chronic adaptation.

Maxwell J, Oxborough D Br Med Bull. 2024; 153(1).

PMID: 39657636 PMC: 11837337. DOI: 10.1093/bmb/ldae021.

The impact of image and performance enhancing drugs on atrial structure and function in resistance trained individuals.

Place F, Carpenter H, Morrison B, Chester N, Cooper R, Stansfield B Echo Res Pract. 2023; 10(1):19.

PMID: 38053157 PMC: 10698975. DOI: 10.1186/s44156-023-00031-y.

Hypertensive Heart Disease-The Imaging Perspective.

Ismail T, Frey S, Kaufmann B, Winkel D, Boll D, Zellweger M J Clin Med. 2023; 12(9).

PMID: 37176563 PMC: 10179093. DOI: 10.3390/jcm12093122.

Heart Reaction to Nandrolone Decanoate plus Two Different Intensities of Endurance Exercise: Electrocardiography and Stereological Approach.

Joukar S, Yoosefnia M, Naderi-Boldaji V, Nasri H, Rafie F Addict Health. 2019; 10(3):180-189.

PMID: 31105916 PMC: 6511393. DOI: 10.22122/ahj.v10i3.587.

References

Urhausen A, Holpes R, Kindermann W . One- and two-dimensional echocardiography in bodybuilders using anabolic steroids. Eur J Appl Physiol Occup Physiol. 1989; 58(6):633-40. DOI: 10.1007/BF00418510. View

Missouris C, Forbat S, Singer D, Markandu N, Underwood R, Macgregor G . Echocardiography overestimates left ventricular mass: a comparative study with magnetic resonance imaging in patients with hypertension. J Hypertens. 1996; 14(8):1005-10. View

Zaugg M, Jamali N, Lucchinetti E, Xu W, Alam M, SHAFIQ S . Anabolic-androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes. J Cell Physiol. 2001; 187(1):90-5. DOI: 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1057>3.0.CO;2-Y. View

Fineschi V, Riezzo I, Centini F, Silingardi E, Licata M, Beduschi G . Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med. 2005; 121(1):48-53. DOI: 10.1007/s00414-005-0055-9. View

DAscenzo S, Millimaggi D, Di Massimo C, Saccani-Jotti G, Botre F, Carta G . Detrimental effects of anabolic steroids on human endothelial cells. Toxicol Lett. 2007; 169(2):129-36. DOI: 10.1016/j.toxlet.2006.12.008. View

Stewart G, Foster J, Cowan M, Rooney E, McDonagh T, Dargie H . Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int. 1999; 56(6):2248-53. DOI: 10.1046/j.1523-1755.1999.00786.x. View

Sader M, Griffiths K, McCredie R, Handelsman D, Celermajer D . Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol. 2001; 37(1):224-30. DOI: 10.1016/s0735-1097(00)01083-4. View

OHanlon R, Grasso A, Roughton M, Moon J, Clark S, Wage R . Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 56(11):867-74. DOI: 10.1016/j.jacc.2010.05.010. View

Hundley W, Bluemke D, Finn J, Flamm S, Fogel M, Friedrich M . ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010; 55(23):2614-62. PMC: 3042771. DOI: 10.1016/j.jacc.2009.11.011. View

10.

Angell P, Chester N, Green D, Somauroo J, Whyte G, George K . Anabolic steroids and cardiovascular risk. Sports Med. 2012; 42(2):119-34. DOI: 10.2165/11598060-000000000-00000. View

11.

Baggish A, Weiner R, Kanayama G, Hudson J, Picard M, Hutter Jr A . Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail. 2010; 3(4):472-6. PMC: 2909423. DOI: 10.1161/CIRCHEARTFAILURE.109.931063. View

12.

Assomull R, Prasad S, Lyne J, Smith G, Burman E, Khan M . Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006; 48(10):1977-85. DOI: 10.1016/j.jacc.2006.07.049. View

13.

MCGILL Jr H, Anselmo V, Buchanan J, Sheridan P . The heart is a target organ for androgen. Science. 1980; 207(4432):775-7. DOI: 10.1126/science.6766222. View

14.

Kasikcioglu E, Oflaz H, Umman B, Bugra Z . Androgenic anabolic steroids also impair right ventricular function. Int J Cardiol. 2008; 134(1):123-5. DOI: 10.1016/j.ijcard.2007.12.027. View

15.

LUKE J, Farb A, Virmani R, Sample R . Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. J Forensic Sci. 1990; 35(6):1441-7. View

16.

Maior A, Menezes P, Pedrosa R, Carvalho D, Soares P, Nascimento J . Abnormal cardiac repolarization in anabolic androgenic steroid users carrying out submaximal exercise testing. Clin Exp Pharmacol Physiol. 2010; 37(12):1129-33. DOI: 10.1111/j.1440-1681.2010.05452.x. View

17.

Wilson M, OHanlon R, Prasad S, Deighan A, MacMillan P, Oxborough D . Diverse patterns of myocardial fibrosis in lifelong, veteran endurance athletes. J Appl Physiol (1985). 2011; 110(6):1622-6. PMC: 3119133. DOI: 10.1152/japplphysiol.01280.2010. View

18.

Simonetti O, Kim R, Fieno D, Hillenbrand H, Wu E, Bundy J . An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001; 218(1):215-23. DOI: 10.1148/radiology.218.1.r01ja50215. View

19.

Weber K, Brilla C, Janicki J . Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res. 1993; 27(3):341-8. DOI: 10.1093/cvr/27.3.341. View

20.

Angell P, Chester N, Green D, Shah R, Somauroo J, Whyte G . Anabolic steroid use and longitudinal, radial, and circumferential cardiac motion. Med Sci Sports Exerc. 2011; 44(4):583-90. DOI: 10.1249/MSS.0b013e3182358cb0. View